Open AccessApplication of the BlandAltman analysis for quantitative assessment of the degree of agreement between drug prescriptions based or not on bioanthropometric data from neurological patients
Author(s) -
Maria Eduarda dos Santos Lopes Vasconcelos,
José Pedro da Silva Sousa,
Cláudio Eduardo Corrêa Teixeira
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.5327/1516-3180.714
Subject(s) - sertraline , clonazepam , citalopram , duloxetine , medicine , topiramate , medical prescription , pharmacology , paroxetine , gabapentin , fluvoxamine , drug , antidepressant , fluoxetine , psychiatry , epilepsy , alternative medicine , receptor , pathology , hippocampus , serotonin
Background: The ability to metabolize, absorb, distribute and eliminate drugs is dependent on the genetic profile of each patient, expressed in their functional, metabolic and bioanthropometric phenotypes. Thus, it is relevant to clarify how much these factors impact (or not) the effectiveness of neurological treatment, since its prescription. Design and setting: cross-sectional study (CAAE: 55048816.3.0000.5169). Methods: To assess the degree of agreement between routinely prescribed drug dose values (standard) and drug dose values calculated based on bioanthropometric data (height and mass) of neurological patients, we performed random data collection from 75 patients, both sexes ,>18 yrs, with prescriptions for the use of: carbamazepine, clonazepam, gabapentin, hydantal, rivotril, topiramate, amitriptyline, bupropion, citalopram, duloxetine, donaren, escitalopram, fluoxetine, imipramine, nortriptyline, paroxetine, venabaletine, venabaletine, sertraline, venabaletine, sertraline, venabaletine, serabaletine, pramipexole, prolopa BD, vertix and zolpidem. Data analysis was performed in R. Results: The application of the Bland-Altman analysis revealed that, on average, the prescribed standard drug dose is~10 units higher or lower than the dose calculated based on bioanthropometric data. That is, there is a ~20% disagreement between these different doses. Conclusions: These results should support new investigations on the impact of these differences on the effectiveness of the adopted neurological treatment.